[Mechanism of the hypocoagulemic effect and the active principle of a phosphatidylserine-containing anticoagulant].
Experiments on animals in vitro showed that phosphatidylserine-containing anticoagulant (PhCA) inhibited factors X and VIII, restricted factor V activity and, to a less degree, that of factor VII, decreased the activity of fibrin-stabilizing factor, the degree of clot retraction and its tolerance to fibrinolysin. The activity of factor IX remained virtually unchanged under the influence of PhCA, whereas the contact phase was speeded up by 14%. Anticoagulant activity of PhCA was accounted for by the phosphatidyl molecule residue - glycerylphosphorylserine.
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D004338:Drug Combinations; D006801:Humans; D066298:In Vitro Techniques; D010714:Phosphatidylethanolamines / Q000494:pharmacology; D010718:Phosphatidylserines / Q000494:pharmacology*; D051381:Rats; D013109:Sphingomyelins / Q000494:pharmacology
D000925:Anticoagulants; D004338:Drug Combinations; D010714:Phosphatidylethanolamines; D010718:Phosphatidylserines; D013109:Sphingomyelins
Mekhanizm gipokoagulemicheskogo éffekta i deĭstvuiushchee nachalo fosfatidilserinsoderzhashchego antikoagulianta.